You are here

Article Text

Article menu

Download PDFPDF

XML
Oncology
Protocol
Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol
  1. Arezoo Rasti1,
  2. Mitra Mehrazma1,2,
  3. Zahra Madjd1,2,3,
  4. Abbas Ali Keshtkar4,
  5. Raheleh Roudi1,
  6. Sadegh Babashah5
  1. 1Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran
  2. 2Department of Pathology, Iran University of Medical Sciences, Tehran, Iran
  3. 3Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
  4. 4Department of Health Sciences Education Development, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  5. 5Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
  1. Correspondence to Dr Mitra Mehrazma; mitmehr{at}yahoo.com
  2. or Dr Zahra Madjd; zahra.madjd{at}yahoo.com

Abstract

Introduction Renal cell carcinoma (RCC) is the most common neoplasm in adult kidneys. One of the most important unmet medical needs in RCC is a prognostic biomarker to enable identification of patients at high risk of relapse after nephrectomy. New biomarkers can help improve diagnosis and hence the management of patients with renal cancer. Thus, this systematic review aims to clarify the prognostic and diagnostic accuracy of miR-21 in patients with RCC.

Methods and analysis We will include observational studies evaluating the diagnostic and prognostic roles of miR-21 in patients with renal cancer. The index test and reference standards should ideally be performed on all patients. We will search PubMed, SCOPUS and ISI Web of Science with no restriction of language. The outcome will be survival measures in adult patients with RCC. Study selection and data extraction will be performed by two independent reviewers. QUADAS-1 will be used to assess study quality. Publication bias and data synthesis will be assessed by funnel plots and Begg's and Egger's tests using Stata software V.11.1.

Ethics and dissemination No ethical issues are predicted. These findings will be published in a peer-reviewed journal and presented at national and international conferences.

Trail registration number This systematic review protocol is registered in the PROSPERO International Prospective Register of Systematic Reviews, registration number CRD42015025001.

  • ONCOLOGY
  • MOLECULAR BIOLOGY

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bmjopen-2015-009667

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text